National Institute of Neurological Disorders and Stroke, Muscular Dystrophy Coordinating Committee Call for Committee Membership Nominations, 5565-5566 [2015-01960]
Download as PDF
<![CDATA[
Federal Register / Vol. 80, No. 21 / Monday, February 2, 2015 / Notices
such payments before funding is offered
to the LRP participant.
Should an IHS Area Office contribute
to the LRP, those funds will be used for
only those sites located in that Area.
Those sites will retain their relative
ranking from the national site-ranking
list. For example, the Albuquerque Area
Office identifies supplemental monies
for dentists. Only the dental positions
within the Albuquerque Area will be
funded with the supplemental monies
consistent with the national ranking and
site index within that Area.
Should an IHS Service Unit
contribute to the LRP, those funds will
be used for only those sites located in
that Service Unit. Those sites will retain
their relative ranking from the national
site-ranking list. For example,
Whiteriver Service Unit identifies
supplemental monies for nurses. The
Whiteriver Service Unit consists of two
facilities, namely the Whiteriver PHS
Indian Hospital and the Cibecue Indian
Health Center. The national ranking will
be used for the Whiteriver PHS Indian
Hospital (Score = 79) and the Cibecue
Indian Health Center (Score = 95). With
a score of 95, the Cibecue Indian Health
Center would receive priority over the
Whiteriver PHS Indian Hospital.
Dated: January 20, 2015.
Yvette Roubideaux,
Acting Director, Indian Health Service.
[FR Doc. 2015–01958 Filed 1–30–15; 8:45 am]
kassilked@mail.nih.gov by Tuesday,
February 17th, 2015. The written
comment should include the
commenter’s name and, when
applicable, professional affiliation.
ADDRESSES: Session 1: February 13,
2015 from 9:30 to 10:00 a.m. https://nih.
webex.com/nih/j.php?MTID=m2a6eb
40ebe096afad861f0b5e941f9bc.
Session 2: February 13, 2015 from
10:00 to 10:30 a.m. https://nih.webex.
com/nih/j.php?MTID=m8c50a
9e8b5454a39b4fa24d9df412fab.
FOR FURTHER INFORMATION CONTACT:
Deborah Kassilke, kassilked@
mail.nih.gov, 301–435–2950.
SUPPLEMENTARY INFORMATION: The
background of the proposed OTT
reorganization is as follows.
The Advisory Committee to the NIH
Deputy Director for Intramural
Research, and the Technology Transfer
Steering Committee (TTSC) recently
assessed OTT to determine how it
services the overall technology transfer
needs of the NIH. The committees
recommended that the authority and
responsibility for the implementation
and execution of patenting and
licensing should be decentralized from
OTT and distributed throughout the
NIH Institutes and Centers (ICs). In
September 2014, the NIH Steering
Committee accepted this
recommendation.
Dated: January 27, 2015.
Lawrence Tabak,
Principal Deputy Director, National Institutes
of Health.
BILLING CODE 4165–16–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
[FR Doc. 2015–01964 Filed 1–30–15; 8:45 am]
BILLING CODE 4140–01–P
National Institutes of Health
Office of Technology Transfer; Notice
of meetings
ACTION:
Notice of meetings.
National Institutes of Health
Notice is hereby given that
the Office of Intramural Research (OIR),
National Institutes of Health (NIH), will
host two webinars to enable public
discussion of its proposal to reorganize
the OIR Office of Technology Transfer
(OTT). The proposal seeks to align
authority and responsibility for the
implementation and execution of
patenting and licensing (P&L) functions
within the NIH Institutes and Centers.
DATES: The first webinar will be held on
February 13th from 9:30 to 10:00 a.m.
The second webinar will be held on
February 13th from 10:00 to 10:30 a.m.
Members of the public wishing to join
a webinar must register via the webinar
link provided. Any interested person
may also file written comments by
sending an email to Deborah Kassilke,
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
19:24 Jan 30, 2015
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Jkt 235001
National Institute of Neurological
Disorders and Stroke, Muscular
Dystrophy Coordinating Committee
Call for Committee Membership
Nominations
The Office of the Secretary of
the Department of Health and Human
Services (HHS) is seeking nominations
of individuals to serve as non-federal
public members on the Muscular
Dystrophy Coordinating Committee.
DATES: Nominations are due by close of
business, February 27, 2015.
ADDRESSES: Nominations must be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen
Nuckolls, Ph.D., by email to nuckollg@
ninds.nih.gov.
SUMMARY:
PO 00000
Frm 00064
Fmt 4703
Sfmt 4703
5565
The
Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory
committee established in accordance
with the Muscular Dystrophy
Community Assistance, Research, and
Education Amendments of 2001 (MD–
CARE Act; Public Law 107–84. The
MD–CARE Act was reauthorized in
2008 by Public Law 110–361, and again
in 2014 by Public Law 113–166. The
2014 reauthorization mandated changes
to the membership of the MDCC,
resulting in the addition of one public
member. Nominations of non-federal
public members will be accepted
between January 30, 2015 and February
27, 2015.
Who is Eligible: Nominations of new
non-federal public members interested
in advancing muscular dystrophy
research and reducing the burden of
disease are encouraged. Selfnominations and nominations of other
individuals are both permitted. Only
one nomination per individual is
required. Multiple nominations for the
same individual will not increase
likelihood of selection. Non-federal
public members may be selected from
the pool of submitted nominations and
other sources as needed to meet
statutory requirements and to form a
balanced committee that represents the
diversity within the muscular dystrophy
community. Those eligible for
nomination include leaders or
representatives of major muscular
dystrophy research, advocacy, and
service organizations, parents or
guardians of individuals with muscular
dystrophy, individuals with muscular
dystrophy and service providers,
educators, researchers, and other
individuals with professional or
personal experience with muscular
dystrophy. In accordance with White
House Office of Management and
Budget guidelines (FR Doc. 2014–
19140), federally-registered lobbyists are
not eligible.
Committee Composition: In
accordance with the Committee’s
authorizing statute, 2⁄3 of members of the
Coordinating Committee shall represent
government agencies and 1⁄3 of members
shall be public members ‘‘including a
broad cross section of persons affected
with muscular dystrophies including
parents or legal guardians, affected
individuals, researchers, and
clinicians.’’
The Department strives to ensure that
the membership of HHS Federal
advisory committees is fairly balanced
in terms of points of view represented
and the committee’s function. Every
effort is made to ensure that the views
of women, all ethnic and racial groups,
SUPPLEMENTARY INFORMATION:
E:\FR\FM\02FEN1.SGM
02FEN1
5566
Federal Register / Vol. 80, No. 21 / Monday, February 2, 2015 / Notices
mstockstill on DSK4VPTVN1PROD with NOTICES
and people with disabilities are
represented on HHS Federal advisory
committees and, therefore, the
Department encourages nominations of
qualified candidates from these groups.
The Department also encourages
geographic diversity in the composition
of the Committee. Appointment to this
Committee shall be made without
discrimination on the basis of age, race,
ethnicity, gender, sexual orientation,
disability, and cultural, religious, or
socioeconomic status. Requests for
reasonable accommodation to enable
participation on the Committee should
be indicated in the nomination
submission.
Member Terms: Non-Federal public
members of the Committee serve for a
term of 3 years, and may serve for an
unlimited number of terms if
reappointed. Members may serve after
the expiration of their terms, until their
successors have taken office.
Meetings and Travel: As specified by
Public Law 113–166, the MDCC ‘‘shall
meet no fewer than two times per
calendar year.’’ Travel expenses are
provided for non-federal public
Committee members to facilitate
attendance at in-person meetings.
Members are expected to make every
effort to attend all full committee
meetings, twice per year, either in
person or via remote access.
Participation in relevant subcommittee,
working and planning group meetings,
and workshops, is also encouraged.
Submission Instructions and
Deadline: Nominations are due by COB
February 27, 2015, and should be sent
to Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov. Nominations
must include contact information for the
nominee, a current curriculum vitae or
resume of the nominee and a paragraph
describing the qualifications of the
person to represent some portion(s) of
the muscular dystrophy research and
patients communities.
More information about the MDCC is
available at https://www.ninds.nih.gov/
about_ninds/groups/mdcc/.
Dated: January 25, 2015.
Walter J. Koroshetz,
Acting Director, National Institute of
Neurological Disorders and Stroke, National
Institutes of Health.
[FR Doc. 2015–01960 Filed 1–30–15; 8:45 am]
BILLING CODE 4140–01–P
VerDate Sep<11>2014
19:24 Jan 30, 2015
Jkt 235001
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Current List of HHS-Certified
Laboratories and Instrumented Initial
Testing Facilities Which Meet Minimum
Standards To Engage in Urine Drug
Testing for Federal Agencies
Substance Abuse and Mental
Health Services Administration, HHS.
ACTION: Notice.
AGENCY:
The Department of Health and
Human Services (HHS) notifies federal
agencies of the laboratories and
Instrumented Initial Testing Facilities
(IITF) currently certified to meet the
standards of the Mandatory Guidelines
for Federal Workplace Drug Testing
Programs (Mandatory Guidelines). The
Mandatory Guidelines were first
published in the Federal Register on
April 11, 1988 (53 FR 11970), and
subsequently revised in the Federal
Register on June 9, 1994 (59 FR 29908);
September 30, 1997 (62 FR 51118);
April 13, 2004 (69 FR 19644); November
25, 2008 (73 FR 71858); December 10,
2008 (73 FR 75122); and on April 30,
2010 (75 FR 22809).
A notice listing all currently HHScertified laboratories and IITFs is
published in the Federal Register
during the first week of each month. If
any laboratory or IITF certification is
suspended or revoked, the laboratory or
IITF will be omitted from subsequent
lists until such time as it is restored to
full certification under the Mandatory
Guidelines.
If any laboratory or IITF has
withdrawn from the HHS National
Laboratory Certification Program (NLCP)
during the past month, it will be listed
at the end and will be omitted from the
monthly listing thereafter.
This notice is also available on the
Internet at https://beta.samhsa.gov/
workplace.
FOR FURTHER INFORMATION CONTACT:
Giselle Hersh, Division of Workplace
Programs, SAMHSA/CSAP, Room 7–
1051, One Choke Cherry Road,
Rockville, Maryland 20857; 240–276–
2600 (voice), 240–276–2610 (fax).
SUPPLEMENTARY INFORMATION: The
Mandatory Guidelines were initially
developed in accordance with Executive
Order 12564 and section 503 of Public
Law 100–71. The ‘‘Mandatory
Guidelines for Federal Workplace Drug
Testing Programs,’’ as amended in the
revisions listed above, requires strict
standards that laboratories and IITFs
must meet in order to conduct drug and
SUMMARY:
PO 00000
Frm 00065
Fmt 4703
Sfmt 4703
specimen validity tests on urine
specimens for federal agencies.
To become certified, an applicant
laboratory or IITF must undergo three
rounds of performance testing plus an
on-site inspection. To maintain that
certification, a laboratory or IITF must
participate in a quarterly performance
testing program plus undergo periodic,
on-site inspections.
Laboratories and IITFs in the
applicant stage of certification are not to
be considered as meeting the minimum
requirements described in the HHS
Mandatory Guidelines. A HHS-certified
laboratory or IITF must have its letter of
certification from HHS/SAMHSA
(formerly: HHS/NIDA), which attests
that it has met minimum standards.
In accordance with the Mandatory
Guidelines dated November 25, 2008
(73 FR 71858), the following HHScertified laboratories and IITFs meet the
minimum standards to conduct drug
and specimen validity tests on urine
specimens:
HHS-Certified Instrumented Initial
Testing Facilities
Gamma-Dynacare Medical Laboratories,
6628 50th Street NW., Edmonton, AB
Canada T6B 2N7, 780–784–1190.
HHS-Certified Laboratories
ACM Medical Laboratory, Inc., 160
Elmgrove Park, Rochester, NY 14624,
585–429–2264.
Aegis Analytical Laboratories, Inc., 345
Hill Ave., Nashville, TN 37210, 615–
255–2400, (Formerly: Aegis Sciences
Corporation, Aegis Analytical
Laboratories, Inc., Aegis Analytical
Laboratories).
Alere Toxicology Services, 1111 Newton
St., Gretna, LA 70053, 504–361–8989/
800–433–3823, (Formerly: Kroll
Laboratory Specialists, Inc.,
Laboratory Specialists, Inc.).
Alere Toxicology Services, 450
Southlake Blvd., Richmond, VA
23236, 804–378–9130, (Formerly:
Kroll Laboratory Specialists, Inc.,
Scientific Testing Laboratories, Inc.;
Kroll Scientific Testing Laboratories,
Inc.).
Baptist Medical Center-Toxicology
Laboratory, 11401 I–30, Little Rock,
AR 72209–7056, 501–202–2783,
(Formerly: Forensic Toxicology
Laboratory Baptist Medical Center).
Clinical Reference Lab, 8433 Quivira
Road, Lenexa, KS 66215–2802, 800–
445–6917.
DrugScan, Inc., 200 Precision Road,
Suite 200, Horsham, PA 19044, 800–
235–4890.
ElSohly Laboratories, Inc., 5 Industrial
Park Drive, Oxford, MS 38655, 662–
236–2609.
E:\FR\FM\02FEN1.SGM
02FEN1
]]>Agencies
[Federal Register Volume 80, Number 21 (Monday, February 2, 2015)]
[Notices]
[Pages 5565-5566]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2015-01960]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute of Neurological Disorders and Stroke, Muscular
Dystrophy Coordinating Committee Call for Committee Membership
Nominations
SUMMARY: The Office of the Secretary of the Department of Health and
Human Services (HHS) is seeking nominations of individuals to serve as
non-federal public members on the Muscular Dystrophy Coordinating
Committee.
DATES: Nominations are due by close of business, February 27, 2015.
ADDRESSES: Nominations must be sent to Glen Nuckolls, Ph.D., by email
to nuckollg@ninds.nih.gov.
FOR FURTHER INFORMATION CONTACT: Glen Nuckolls, Ph.D., by email to
nuckollg@ninds.nih.gov.
SUPPLEMENTARY INFORMATION: The Muscular Dystrophy Coordinating
Committee (MDCC) is a federal advisory committee established in
accordance with the Muscular Dystrophy Community Assistance, Research,
and Education Amendments of 2001 (MD-CARE Act; Public Law 107-84. The
MD-CARE Act was reauthorized in 2008 by Public Law 110-361, and again
in 2014 by Public Law 113-166. The 2014 reauthorization mandated
changes to the membership of the MDCC, resulting in the addition of one
public member. Nominations of non-federal public members will be
accepted between January 30, 2015 and February 27, 2015.
Who is Eligible: Nominations of new non-federal public members
interested in advancing muscular dystrophy research and reducing the
burden of disease are encouraged. Self-nominations and nominations of
other individuals are both permitted. Only one nomination per
individual is required. Multiple nominations for the same individual
will not increase likelihood of selection. Non-federal public members
may be selected from the pool of submitted nominations and other
sources as needed to meet statutory requirements and to form a balanced
committee that represents the diversity within the muscular dystrophy
community. Those eligible for nomination include leaders or
representatives of major muscular dystrophy research, advocacy, and
service organizations, parents or guardians of individuals with
muscular dystrophy, individuals with muscular dystrophy and service
providers, educators, researchers, and other individuals with
professional or personal experience with muscular dystrophy. In
accordance with White House Office of Management and Budget guidelines
(FR Doc. 2014-19140), federally-registered lobbyists are not eligible.
Committee Composition: In accordance with the Committee's
authorizing statute, \2/3\ of members of the Coordinating Committee
shall represent government agencies and \1/3\ of members shall be
public members ``including a broad cross section of persons affected
with muscular dystrophies including parents or legal guardians,
affected individuals, researchers, and clinicians.''
The Department strives to ensure that the membership of HHS Federal
advisory committees is fairly balanced in terms of points of view
represented and the committee's function. Every effort is made to
ensure that the views of women, all ethnic and racial groups,
[[Page 5566]]
and people with disabilities are represented on HHS Federal advisory
committees and, therefore, the Department encourages nominations of
qualified candidates from these groups. The Department also encourages
geographic diversity in the composition of the Committee. Appointment
to this Committee shall be made without discrimination on the basis of
age, race, ethnicity, gender, sexual orientation, disability, and
cultural, religious, or socioeconomic status. Requests for reasonable
accommodation to enable participation on the Committee should be
indicated in the nomination submission.
Member Terms: Non-Federal public members of the Committee serve for
a term of 3 years, and may serve for an unlimited number of terms if
reappointed. Members may serve after the expiration of their terms,
until their successors have taken office.
Meetings and Travel: As specified by Public Law 113-166, the MDCC
``shall meet no fewer than two times per calendar year.'' Travel
expenses are provided for non-federal public Committee members to
facilitate attendance at in-person meetings. Members are expected to
make every effort to attend all full committee meetings, twice per
year, either in person or via remote access. Participation in relevant
subcommittee, working and planning group meetings, and workshops, is
also encouraged.
Submission Instructions and Deadline: Nominations are due by COB
February 27, 2015, and should be sent to Glen Nuckolls, Ph.D., by email
to nuckollg@ninds.nih.gov. Nominations must include contact information
for the nominee, a current curriculum vitae or resume of the nominee
and a paragraph describing the qualifications of the person to
represent some portion(s) of the muscular dystrophy research and
patients communities.
More information about the MDCC is available at https://www.ninds.nih.gov/about_ninds/groups/mdcc/.
Dated: January 25, 2015.
Walter J. Koroshetz,
Acting Director, National Institute of Neurological Disorders and
Stroke, National Institutes of Health.
[FR Doc. 2015-01960 Filed 1-30-15; 8:45 am]
BILLING CODE 4140-01-P
